Post by Bristol Myers Squibb

This year at #EHA26, we’re showcasing new pipeline data, particularly from our transformative therapeutic class known as CELMoD, representing progress in the treatment of hematologic diseases like multiple myeloma and lymphoma. Congresses like the European Hematology Association (EHA) Conference bring together the greatest minds in hematology to drive progress in the treatment and care of people living with blood diseases. Read about our CELMoD research: https://bit.ly/4e5b1wi #OneBMS